AbbVie (ABBV) Total Non-Current Liabilities (2012 - 2026)

AbbVie (ABBV) has 15 years of Total Non-Current Liabilities data on file, last reported at $109.0 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $109.0 billion, down 2.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $109.0 billion (down 2.7% YoY), and the FY2025 annual result was $104.6 billion, down 5.0% from the prior year.
• Total Non-Current Liabilities improved to $109.0 billion in Q1 2026 per ABBV's latest filing, from $104.6 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $120.7 billion in Q1 2024 and troughed at $103.3 billion in Q1 2023.
• A 5-year average of $109.1 billion and a median of $109.0 billion in 2026 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities dropped 9.53% in 2022, then climbed 16.8% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $105.1 billion in 2022, then dropped by 0.68% to $104.4 billion in 2023, then gained by 5.47% to $110.1 billion in 2024, then retreated by 5.0% to $104.6 billion in 2025, then increased by 4.15% to $109.0 billion in 2026.
• Business Quant data shows ABBV's Total Non-Current Liabilities at $109.0 billion in Q1 2026, $104.6 billion in Q4 2025, and $104.9 billion in Q3 2025.